logo-loader

C4X Discovery shifts focus to immuno-inflammatory diseases

Last updated: 04:03 27 Mar 2024 EDT, First published: 01:02 15 Apr 2021 EDT

Snapshot

  • C4X Discovery CEO says delisting decision not taken lightly
  • C4X Discovery succeeding in the face of some tough market headwinds
  • C4X Discovery payment ‘strong validation’ of firm’s prowess - analyst
  • C4X Discovery "really well capitalised and focused" heading into new year
researcher

About the company

C4X Discovery Holdings PLC is a pioneering drug discovery company combining scientific expertise with cutting-edge drug discovery technologies to efficiently deliver world leading medicines.

The company has a highly valuable and differentiated approach to drug discovery through its enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders.

C4X Discovery's commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage drug discovery programmes ready for out-licensing to partners and it has two commercially partnered programmes with one candidate in clinical development.

How it is doing

27 Mar 2024

C4X Discovery Holdings PLC (AIM:C4XD) CEO Clive Dix said the decision to delist the drug developer had not been taken lightly, but added the downturn in financial markets had impacted its "future ability to raise funds in the public markets".

In the release confirming these plans, he added: "The board believes the current public market valuation does not reflect the underlying potential of our business or our achievements to date and that this is unlikely to change in the short-to-medium term.

"We believe that we can potentially access a larger quantum of future funding required to accelerate our strategy as a private company and therefore we believe that a cancellation of the company's admission on AIM is in the best interest for shareholders and for the future of our business as a whole."

He pointed out that C4X had been given very little credit by the market for three transactions with major pharma companies, or recognition for its deal-making and scientific expertise.

11 Jan 2024

C4X Discovery Holdings PLC (AIM:C4XD), a Manchester-based biotechnology company, is making significant strides in the field of immuno-inflammatory disease, executing a new and ‘evolutionary’ strategy.

The move forms part of the company’s strategy to focus on immuno-inflammatory pathways and to progress further along the development pathway, a core shift in its business model initiated last year. 

03 Jan 2024

C4X Discovery Holdings PLC (AIM:C4XD) has reached what has been described as a "significant milestone" after receiving an US$11 million payment under its US$402 million deal with pharma giant AstraZeneca PLC (LSE:AZN).

Specifically, the financial landmark marks the progression of the NRF2 Activator programme, created by C4XD and outlicensed to AZ.

Insight: C4X Discovery succeeding in the face of some tough market headwinds

19 Feb 2024

A marked decline in the value of AIM-listed healthcare stocks over the past two-and-a-half years belies the significant progress being made behind the scenes at these innovative companies.

A case in point is C4X Discovery Holdings PLC (AIM:C4XD), which has two licensing agreements under its belt with blue-chip partners, has sold an asset and, crucially, is funded for the foreseeable future.

What the brokers say

03 Jan 2024

News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.

Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Capital analysts backed aim-listed C4X.

“We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note.

What management says

04 Jan 2024

 

C4X Discovery Holdings PLC (AIM:C4XD) Chief Business Officer Bhavna Hunjan and Chief Scientific Officer Nick Ray speak to Thomas Warner from Proactive after the drug discovery company announced receipt of a US$11 million payment under its US$402 million deal with pharma giant AstraZeneca PLC (LSE:AZN).

Specifically, the financial landmark marks the progression of the NRF2 Activator programme, created by C4XD and outlicensed to AZ. Nick Ray elaborates on NRF2, a molecule critical in regulating cellular oxidative stress and inflammatory responses, saying that the discovery has potential applications in various inflammatory diseases like COPD, sickle cell disease, and multiple sclerosis.